Compare DigitalOcean Holdings Inc (DOCN) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DigitalOcean Holdings Inc vs Inovio Pharmaceuticals Inc — how do they compare? DigitalOcean Holdings Inc trades at $132 (market cap $13.18B), while Inovio Pharmaceuticals Inc trades at $1.19 (market cap $95.85M). The key difference: DigitalOcean Holdings Inc is far larger — about 137.5× Inovio Pharmaceuticals Inc's market cap, and DigitalOcean Holdings Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| DOCN | INO | |
|---|---|---|
Market Cap | $13.18B | $95.85M |
Sector | Technology | Health |
52-Week High | $181.29 | $2.87 |
52-Week Low | $25.74 | $1.05 |
Enterprise Value | $13.74B | $66.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DigitalOcean (DOCN) trades at $123.32, down 5.49% today, with bearish technical signals but strong fundamental performance. The company reported record Q2 2026 results with revenue exceeding expectations and significant AI-driven growth. Analyst consensus remains bullish with a $174.80 price target, though technical indicators show selling pressure near-term.
The outlook remains positive given strong AI adoption and enterprise wins, with 63% analyst buy ratings supporting upside potential. Key risks include high valuation multiples and competitive cloud market pressures. The stock's current weakness presents a potential entry point for growth investors seeking AI infrastructure exposure.
INO trades at $1.16, down 1.69% on the day, with a bearish technical outlook from moving averages. The company shows minimal revenue of $65.34K in 2025 and a net loss of $84.95M, resulting in a negative net margin of 130,000%. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, alongside shareholder litigation concerns.
The investment case hinges on the binary FDA decision for INO-3107, offering high upside potential but significant risk. Analyst consensus is moderately positive with 53% buy ratings, yet fundamental weaknesses and negative cash flows pose substantial risks for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
